Showing 20 of 117 recruiting trials for “acute-myeloid-leukemia-with-t816p11p13-translocation”
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
CAV Regimen for R/R AML
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
👨⚕️ Alice S Mims, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Sep 2022View details ↗
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
RecruitingNCT05290662 ↗
Registry of Patients Having Received oNKord®
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
👨⚕️ Melinda Pauley, MD, Emory University, Children's Healthcare of Atlanta📍 3 sites📅 Started Apr 2022View details ↗
RecruitingNCT05326919 ↗
The Patient Cohort of the National Center for Precision Medicine in Leukemia
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
👨⚕️ Depei Wu, MD. PhD, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Sep 2021View details ↗
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →